samirhuli,
Regarding pharma stocks I am not too sure at this stage which co from among the ones u mentioned is going to create the max wealth. But most of the US facing pharma companies who dont have regulatory hurdles are sitting pretty and are on track to make decent gains in next few years.
Regarding your comments about missing the bus, in case of the stock you are tracking or the girl you are wooing, its never too late to take the plunge. 
In investing,
This is not pointed towards anyone, just my view based on my experience.
In investing,
This is not pointed towards anyone, just my view based on my experience.
One reason why EBITA margins for cable companies have increased in the recent past is because of the reduction in raw material prices (refer to Vindhya Telelink’s last qtrs “Cost of materials consumed” against same quarter last year). One needs to take a call based on how long these raw material prices will be favourable.
Disc: Not invested.
Thanks. Will wait to educate myself on if PE can/should be used or not. At this point in time I am not equipped enough to be able to compare between both and hence would refrain from talking about pros and cons of both approaches in relative terms.
Personally, I just try to follow a basic thing which is valuation approach for a firm should be driven by where the value is created from or where the value lies within the firm. And hence have been able to reconcile with book value (alongwith other associated stuff as stated above) as a good approach to value banks or NBFCs.
Also believe that such theories need to deliberated much in detail with appropriate back testing etc.,. as well. Don’t think I have the time to deliberate that much but none the less will try to read what I can find on this 
Warren Buffet is against cyclical stock for simple reason that average cash flow over a period of time is not so fantastic because of negative return during down turn of cycle. At the same time many renowned players have advocated for cyclical sector because they offer us safe entry during down turn.
I invite all estimated valuePicker colleagues to join me and embark on this wonderful journey of big bull run in Shree Renuka which has just commenced.
Shree Renuka is right now resting on three strong pillars which form strong foundation which creats case for superior returns in medium to long term as under:
(1). Cyclicals: Timing is everything in cyclical sector. If we pick the stock at down turn of cycle and exit at up turn, it offers multi fold returns.
(2). Turn around: When company is turning the corner, it is available at throw away price due to debt laden position of company. History is full of such companies which passes through rough whether and come out with flying colours. With kind of dynamism Mr. Murukumbi has shown in establishing Shree Renuka, it is ripe for big turn around at this stage.
(3). Asset plays: Because of huge assets owned by company stock available at discounted price is as good as by asset at discounted rates when sector is in recession. Sugar sector is offering best opportunity because of consecutive 5 years of surplus in international sugar market.
Above three are criteria out of six categories identified by non other than Peter Lynch. The veteran who has coined the term Multi bagger.
Technical terms Sugar cycle has taken U turn at international level and new new bull run has started with bottom in place. Shree Renuka is only international sugar company from India who has managed to escape controls of states and Indian government to some extent. With rich experience of Wilmar group in trading of agro items lot of synergy has come in to existence.
While management is writing turn around story of Shree renuka, I am pleased to invite you all to share your valuable experience.
Sugarbull.
Few pointers from my talk with the CS of NCL Industries
He was resistant to divulge any info for current quarter.
Regards
Sri Krishna Bhutra
Some updates post 2Q results from broker reports…..
The management has covered their raw material costs for the year through long-term contracts. Hence, 2Q gross margin expansion of 299bps is likely to continue in 2HFY16. The company has tied up with a third-party manufacturer in East India for supplying beverages in that market from 4QFY16 onwards at favourable terms. This, in turn, will protect gross margin of the business and help the company save on transportation costs as it was supplying the product from Chennai till date.
The management is confident of delivering 5% volume growth in the OTC business, with 5-6% of price increase in its core pain relieving balm. New format products like back-pain roll-on and feminine hygiene products are expected to grow 100% this year. The beverage business will deliver ~17-18% growth this year, given that 1HFY16 was subdued on account of a short summer and disruption in business due to assigning a third-party manufacturer for the eastern
region.
Totally agree with that. Have been with Page for reasonably long time. Had missed the Eicher ride, have boarded it recently in its pit stop – hoping “Intelligent Fanatic” Siddharth Lal will ensure it will be an enjoyable ride
Hi @hrfacebuk: I do not have specific references. But if you can go through old threads of HDFC Bank, Gruh on The Equity Desk, it would clear the point.
Also please read entire threads of Gruh and Repco on ValuePickr. We have discussed this a lot of times.
@bharti_vishal has covered what would happen if Repco were to get usual 2-3 PB in his comment above. I think that explains it well.